Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)
Authors
Qaseem, AmirYost, Jennifer
Etxeandia-Ikobaltzeta, Itziar
Abraham, George M.
Jokela, Janet A.
Forciea, Mary Ann
Miller, Matthew C.
Humphrey, Linda L.
UMass Chan Affiliations
Department of MedicineDocument Type
ArticlePublication Date
2021-02-09Keywords
remdesivirhospitalized patients
coronavirus disease 2019
COVID-19
effectiveness
harms
Health Services Administration
Health Services Research
Infectious Disease
Internal Medicine
Patient Safety
Therapeutics
Virus Diseases
Metadata
Show full item recordAbstract
Practice points for clinicians developed by the American College of Physicians addressing these questions: What are the effectiveness and harms of remdesivir in hospitalized patients with coronavirus disease 2019 (COVID-19)? Do effectiveness and harms in hospitalized patients with COVID-19 vary by symptom duration, disease severity, and treatment duration?Source
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). Ann Intern Med. 2021 Feb 9. doi: 10.7326/M20-8101. Epub ahead of print. PMID: 33560862. Link to article on publisher's site
DOI
10.7326/M20-8101Permanent Link to this Item
http://hdl.handle.net/20.500.14038/27381PubMed ID
33560862Related Resources
ae974a485f413a2113503eed53cd6c53
10.7326/M20-8101